Gastrointestinal side effects of drugs

Expert Opinion on Drug Safety

Volumn 2, Issue 4, 2003, Pages 421-429

  Makins, Richard ^a   Ballinger, Anne ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

adverse effect; colitis; drugs; gastrointestinal (GI) tract; peptic ulcers

Indexed keywords

DRUG;

CHEMICALLY INDUCED DISORDER; ENTEROPATHY; ESOPHAGUS DISEASE; GASTROINTESTINAL DISEASE; HUMAN; MOUTH DISEASE; PANCREATITIS; REVIEW; STOMACH DISEASE;

ESOPHAGEAL DISEASES; GASTROINTESTINAL DISEASES; HUMANS; INTESTINAL DISEASES; MOUTH DISEASES; PANCREATITIS; PHARMACEUTICAL PREPARATIONS; STOMACH DISEASES;

EID: 0141595161     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.4.421     Document Type: Review

References (76)

1. WYNN RL, MEILLER TF: Drugs and dry mouth. Gen. Dent. (2001) 49:10-14.
2. APPELL RA: The newer antimuscarinic drugs: bladder control with less dry mouth. Cleve. Clin. J. Med. (2002) 69:761-769. (Pubitemid 35214738)
3. DONGARI A, MCDONNELL HT, LANGLAIS RP: Drug-induced gingival overgrowth. Oral Surg. Oral Med. Oral Pathol. (1993) 76:543-548. (Pubitemid 23318943)
4. ELLIS JS, SEYMOUR RA, STEELE JG et al.: Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. J. Peridontol. (1999) 70:63-67. (Pubitemid 29076012)
5. FATTORE L, STABLEIN M, BREDFELDT G et al.: Gingival hyperplasia: a side effect of nifedipine and diltiazem. Spec. Care Dent. (1991) 11:107-109.
6. MCGAW WT, PORTER H: Cyclosporine-induced gingival overgrowth: an ultrastructural stereologic study. Oral Surg. Oral Med. Oral Pathol. (1988) 65:186-190. (Pubitemid 18062292)
7. CECCHIN E, ZANELLO F, DE MARCHI S: Treatment of cyclosporine-induced gingival hypertrophy. Ann. Intern. Med. (1997) 126:409-410.
8. GUGGENHEIMER J: Tetracyclines and human dentition. Compend. Contin. Educ. Dent. (1984) 5:245-254.
9. GUGGENHEIMER J: Oral manifestations of drug therapy. Dent. Clin. North Am. (2002) 46:857-868.
10. MOTT AE, GRUSHKA M, SESSLE BJ: Diagnosis and management of taste disorders and burning mouth syndrome. Dent. Clin. North Am. (1993) 37:33-71.
11. POTTS AJ, HAMBURGER J, SCULLY C: The medication of patients with oral lichen planus and the association of nonsteroidal anti-inflammatory drugs with erosive lesions. Oral Surg. Oral Med. Oral Path. (1987) 64:541-543.
12. BEZ C, LODI G, SARDELLA A, DELLA VOLPE A, CARRASSI A: Oral lichenoid lesions after thalidomide treatment. Dermatology (1999) 199:195. (Pubitemid 29494811)
13. SCULLY C, DIZ DIOS P: Orofacial effects of antiretroviral therapies. Oral Dis. (2001) 7:205-210. (Pubitemid 32734917)
14. MACARIO-BARREL A, TANASESCU S, COURVILLE P et al.: Mouth ulcers in patients receiving tacrolimus. Ann. Dermatol. Venereol. (2001) 128:1327-1329.
15. PALERI V, LINDSEY L: Oral ulcers caused by hydroxyurea. J. Laryngol. Otol. (2000) 114:976-977. (Pubitemid 32105517)
16. SCULLY C, AZUL AM, CRIGHTON A et al.: Nicorandil can induce severe oral ulceration. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. (2001) 91:189-193. (Pubitemid 33601632)
17. MARQUART-ELBAZ C, LIPSKER D, GROSSHANS E, CRIBIER B: Oral ulcers induced by nicorandil: prevalence and clinicopathological aspects. Ann. Dermatol. Venereol. (1999) 126:587-590. (Pubitemid 29470235)
18. DEMERJIAN N, BOLLA G, SPREUX A: Severe oral ulceration induced by alendronate. Clin. Rheumatol. (1999) 18:349-350. (Pubitemid 29369552)
19. REDDING SW, HAVEMAN CW: Treating the discomfort of oral ulceration resulting from cancer chemotherapy. Compend. Contin. Educ. Dent. (1999) 20:389-396.
20. COHEN DM, BHATTACHARYYA I, LYDIATT WM: Recalcitrant oral ulcers caused by calcium channel blockers: diagnosis and treatment considerations. J. Am. Dent. Assoc. (1999) 130:1611-1618.
21. COHEN DM BHATTACHARYYA I: Cinnamon-induced oral erythema multiforme-like sensitivity reaction. J. Am. Dent. Assoc. (2000) 131:929-934.
22. SLOMIANY BL, SLOMIANY A: Aspirin ingestion impairs oral mucosal ulcer healing by inducing membrane-bound tumour necrosis factor-α release. IUBMB Life (2000) 50:391-395. (Pubitemid 32285203)
23. JASPERSEN D: Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Saf. (2000) 22:237-249. (Pubitemid 30157584)
24. YAP I, GUAN R, KANG JY et al.: Pill-induced oesophageal ulcer. Singapore Med. J. (1993) 34:257-258.
25. SMITH SJ, LEE AJ, MADDIX DS, CHOW AW: Pill-induced oesophagitis caused by oral rifampicin. Ann. Pharmacother. (1999) 33:27-31. (Pubitemid 29056554)
26. BOTT SJ, MCCALLUM RW: Medication-induced oesophageal injury. Survey of the literature. Med. Toxicol. (1986) 1:449-457. (Pubitemid 17208175)
27. HELLER SR, FELLOWS IW, OGILVIE AL, ATKINSON M: Non-steroidal anti-inflammatory drugs and benign oesophageal stricture. Br. Med. J. (1982) 285:167-168. (Pubitemid 12079066)
28. KIM SL, HUNTER JG, WO JM et al.: NSAIDs, aspirin and oesophageal strictures: are over-the-counter medications harmful to the oesophagus? J. Clin. Gastroenterol. (1999) 29:32-34. (Pubitemid 29288199)
29. WILKINS WE, RIDLEY MG, POZNIAK AL: Benign stricture of the oesophagus: role of non-steroidal anti-inflammatory drugs. Gut (1984) 25:478-480. (Pubitemid 14144020)
30. LONG JD, ORLANDO RC: Eicosanoids and the oesophagus. Dig. Dis. (1997) 15:145-154.
31. MACONI G, PORRO GB: Multiple ulcerative esophagitis caused by alendronate. Am. J. Gastroenterol. (1995) 90:1889-1890.
32. DE GROEN PC, LUBBE DF, HIRSCH LJ et al.: Esophagitis associated with the use of alendronate. N. Engl. J. Med. (1996) 335:1016-1021. (Pubitemid 26338731)
33. MARSHALL JK, RAINSFORD KD, JAMES C, HUNT RH: A randomised controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment. Pharmacol. Ther. (2000) 14:1451-1457.
34. GRAHAM DY: What the gastroenterologist should know about the gastrointestinal safety profile of bisphosphonates. Dig. Dis. Sci. (2002) 47:1665-1678. (Pubitemid 34833194)
35. ELLIOTT SN MCKNIGHT W, DAVIES NM et al.: Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci. (1998) 62:77-91. (Pubitemid 28132976)
36. JONES KR, PILLSBURY HC III: Cellulose fiber diet pills. A new cause of oesophageal obstruction. Arch. Otolaryngol. Head Neck Surg. (1990) 116:1091. (Pubitemid 20277086)
37. VAN DER VOORT PH, VAN ROON EN, GROND AI et al.: Eosophageal rupture with aortic-esophageal fistula due to ingestion of foil packaged drugs. Ned. Tijdschr. Geneeskd (2001) 145:1991-1994. (Pubitemid 32958692)
38. ALLEN M, MELLOW M, ROBINSON MG, ORR WC: Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function. Aliment. Pharmacol. Ther. (1987) 1:153-159.
39. ISHIKAWA H, IWAKIRI K, SUGIURA T, KOBAYASHI M: Effect of nifedipine administration (10 mg) on esophageal acid exposure. J. Gastroenterol. (2000) 35:43-46. (Pubitemid 30072280)
40. NASSAR NN, GREGG CR: Oesophageal infections. Curr. Treat. Options Gastroenterol. (1998) 1:56-63.
41. ORTUNA CORTES JA, TOVAR MARTINEZ A, RUIZ RIQUELME J et al.: Esophageal candidiasis in HIV-negative patients. Rev. Esp. Enferm. Dig. (1997) 89:503-510.
42. CHOCARRO MARTINEZ A, GALINDO TOBAL F, RUIZ-IRASTORZA G et al.: Risk factors for esophageal candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. (2000) 19:96-100. (Pubitemid 30139394)
43. JONES MK, WANG H, PESKAR BM et al.: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. (1999) 5:1418-1423.
44. LARKAI EN, SMITH JL, LIDSKY MD, GRAHAM DY: Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am. J. Gastroenterol. (1987) 82:1153-1158. (Pubitemid 18013110)
45. WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (1999) 340:1888-1899. (Pubitemid 29272670)
46. ALLISON MC, HOWATSON AG, TORRANCE CJ: Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (1992) 327:749-754.
47. BALLINGER AB, SMITH G: COX-2 vs NSAIDs: gastrointestinal damage and prevention. Exp. Opin. Pharmacother. (2001) 2:31-40. (Pubitemid 32427712)
48. GRAHAM DY, MALATY HM: Alendronate and naproxen are synergistic for development of gastric ulcers. Arch. Intern. Med. (2001) 161:107-110. (Pubitemid 32052151)
49. SAVAGE RL, MOLLER PW, BALLANTYNE CL, WELLS JE: Variation in the risk of peptic ulcer complications with nonsteroidal anti-inflammatory drug therapy. Arthritis Rheum. (1993) 36:84-90. (Pubitemid 23048683)
50. LANGMAN MJ, WEIL J, WAINWRIGHT P et al.: Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 343:1075-1078.
51. DE ABAJO FJ, GARCIA RODRIGUEZ LA, MONTERO D: Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population-based case-control study. Br. Med. J. (1999) 319:1106-1109. (Pubitemid 29494721)
52. GARCIA RODRIGUEZ LA, HERNANDEZ-DIAZ S, DE ABAJO FJ: Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br. J. Clin. Pharmacol. (2001) 52:563-571.
53. HAWKEY CJ, WILSON I, NAESDAL J, LANGSTROM G, SWANNELL AJ, YEOMANS ND: Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut (2002) 51:344-350.
54. GARCIA RODRIGUEZ LA, HERNANDEZ-DIAZ S: Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology (2001) 12:570-576. (Pubitemid 32762000)
55. SIMON LS, WEAVER AL, GRAHAM DY et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 282:1921-1928.
56. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N. Engl. J. Med. (2000) 343:1520-1528.
57. WRIGHT JM: The double-edged sword of COX-2 selective NSAIDs. Can. Med. Assoc. J. (2002) 167:1131-1137.
58. SMALE S, TIBBLE J, SIGTHORSSON G, BJARNASON I: Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine. Best Pract. Res. Clin. Gastroenterol. (2001) 15:723-738. (Pubitemid 32982362)
59. SMOGER SH, SAYED MA: Simultaneous mucosal and small bowel angioedema due to captopril. South. Med. J. (1998) 91:1060-1063. (Pubitemid 28524392)
60. PUSPOK A, KIENER HP, OBERHUBER G: Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon. Dis. Colon Rectum (2000) 43:685-691. (Pubitemid 30324609)
61. COX J, DANESHMEND TK, HAWKEY CJ, LOGAN RF, WALT RP: Devastating diarrhoea caused by azathioprine: management difficulty in inflammatory bowel disease. Gut (1988) 29:686-688.
62. ROSA I, NAHON S, COHEN C et al.: Ticlopidine-induced lymphocytic colitis. Ann. Med. Interne (1999) 150:437-439. (Pubitemid 29482655)
63. BAERT F, WOUTERS K, D'HAENS G et al.: Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut (1999) 45:375-381. (Pubitemid 29400713)
64. PREVENTZA OA, LAZARIDES K, SAWYER MD: Ischemic colitis in young adults: a single-institution experience. J. Gastrointest. Surg. (2001) 5:388-392. (Pubitemid 33651254)
65. ABLIN DS, ZIEGLER M: Ulcerative type of colitis associated with the use of high strength pancreatic enzyme supplements in cystic fibrosis. Pediatr. Radiol. (1995) 25:113-115.
66. SMYTH RL, VAN VELZEN D, SMYTH RA et al.: Strictures of the ascending colon in cystic fibrosis and high-strength pancreatic enzyme supplements. Lancet (1994) 343:85-86. (Pubitemid 24019350)
67. VAN VELZEN D, BALL LM, DEZFULIAN AR, SOUTHGATE A, HOWARD CV: Comparative and experimental pathology of fibrosing colonopathy. Postgrad. Med. J. (1996) 72:S39-S48. (Pubitemid 126733521)
68. LLOYD-STILL JD: Cystic fibrosis and colonic strictures: a new 'iatrogenic' disease. J. Clin. Gastroenterol. (1995) 21:2-5.
69. BANSI DS, PRICE A, RUSSELL C, SARNER M: Fibrosing colonopathy in an adult owing to overuse of pancreatic enzyme supplements. Gut (2000) 46:283-285. (Pubitemid 30305858)
70. VANEK VW, AL-SALTI M: Acute pseudo-obstruction of the colon (Ogilvie's syndrome). An analysis of 400 cases. Dis. Colon Rectum (1986) 29:203-210. (Pubitemid 16124078)
71. LANKISCH PG, DROEGE M, GOTTESLEBEN F: Drug-induced acute pancreatitis: incidence and severity. Gut (1995) 37:565-567.
72. MCARTHUR KE: Drug-induced pancreatitis. Aliment. Pharmacol. Ther. (1996) 10:23-27.
73. RUNZI M, LAYER P: Drug-associated pancreatitis: facts and fiction. Pancreas (1996) 13:100-109. (Pubitemid 26187777)
74. MILMINICK T, FRICK TW: Drug-induced pancreatitis. Drug Saf. (1996) 14:406-409.
75. ANDERSEN V, SONNE J, ANDERSEN M: Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. Eur. J. Clin. Pharmacol. (2001) 57:517-521.
76. MALLORY A, KERN F Jr: Drug-induced pancreatitis: a critical review. Gastroenterology (1980) 78:813-820. (Pubitemid 10111949)